Want to see AMPH full AI Analyst Report?
AMPH Stock Chart & Stats
$21.98
-$0.15(-0.79%)
At close: 4:00 PM EDT
$21.98
-$0.15(-0.79%)
Day’s Range― - ―
52-Week Range$16.65 - $29.52
Previous Close$18.72
Volume445.68K
Average Volume (3M)488.95K
Market Cap
$1.11B
Enterprise Value$1.29B
Total Cash (Recent Filing)$290.12M
Total Debt (Recent Filing)$688.32M
Price to Earnings (P/E)14.9
Beta0.67
Next Earnings
Nov 09, 2026EPS Estimate
0.86Next Dividend Ex-DateN/A
Dividend Yield3.43%
Share Statistics
EPS (TTM)1.74
Shares Outstanding42,537,945
10 Day Avg. Volume431,874
30 Day Avg. Volume488,953
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)1.59
Price to Sales (P/S)1.74
P/FCF Ratio10.33
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue1.76
Enterprise Value/Gross Profit3.70
Enterprise Value/Ebitda6.74
Forecast
1Y Price Target
$22.17Price Target Upside0.85% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)2.97
Revenue Forecast (FY)$747.81M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationStrong operating and free cash flow supports earnings quality, internal funding of manufacturing and pipeline investment, and financial resilience. This cash generation gives Amphastar flexibility to absorb operating volatility, pursue product development, and return capital without relying as heavily on external financing.
New Products Support Growth And MarginsRecent complex-generic launches are adding revenue while improving the product mix and gross margin. Successful commercialization and production at Armstrong demonstrate execution capabilities that can support a broader portfolio, helping offset declines in older products over the next several quarters.
BAQSIMI Franchise And MilestonePrescription growth confirms continued demand for BAQSIMI, while the achieved sales threshold creates a substantial near-term cash inflow. The franchise provides an important earnings and funding contributor, supporting Amphastar’s ability to invest in its pipeline and commercial platform.
Bears Say
IMS FDA Remediation RiskThe warning letter creates a sustained compliance and execution burden at a manufacturing subsidiary. Remediation costs can pressure profits, while slower batch releases or IMS sales could disrupt product availability and reduce the contribution of a business representing roughly one-third of corporate sales.
Structural Glucagon DeclineGlucagon is facing competitive erosion that management does not expect to reverse in the near term. Continued revenue contraction would reduce the contribution of an established product, require replacement growth from newer launches, and make portfolio growth more dependent on successful commercialization.
Margin And Operating Leverage PressureProfitability has normalized sharply from earlier peaks, indicating that prior margin levels are not currently sustainable. Higher selling, administrative, legal, ERP, and development costs may continue to constrain operating leverage, leaving less of future revenue growth to flow through to earnings.
Amphastar Pharmaceuticals News
AMPH FAQ
What was Amphastar Pharmaceuticals’s price range in the past 12 months?
Amphastar Pharmaceuticals lowest stock price was $16.64 and its highest was $29.52 in the past 12 months.
What is Amphastar Pharmaceuticals’s market cap?
Amphastar Pharmaceuticals’s market cap is $1.11B.
When is Amphastar Pharmaceuticals’s upcoming earnings report date?
Amphastar Pharmaceuticals’s upcoming earnings report date is Nov 09, 2026 which is in 20 days.
How were Amphastar Pharmaceuticals’s earnings last quarter?
Amphastar Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.29.
Is Amphastar Pharmaceuticals overvalued?
According to Wall Street analysts Amphastar Pharmaceuticals’s price is currently Undervalued.
Does Amphastar Pharmaceuticals pay dividends?
Amphastar Pharmaceuticals pays a Annually dividend of $0.3 which represents an annual dividend yield of 3.43%. See more information on Amphastar Pharmaceuticals dividends here
What is Amphastar Pharmaceuticals’s EPS estimate?
Amphastar Pharmaceuticals’s EPS estimate is 0.86.
How many shares outstanding does Amphastar Pharmaceuticals have?
Amphastar Pharmaceuticals has 42,537,945 shares outstanding.
What happened to Amphastar Pharmaceuticals’s price movement after its last earnings report?
Amphastar Pharmaceuticals reported an EPS of $0.91 in its last earnings report, beating expectations of $0.62. Following the earnings report the stock price went up 4.897%.
Which hedge fund is a major shareholder of Amphastar Pharmaceuticals?
Currently, no hedge funds are holding shares in AMPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amphastar Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$22.17 (0.85% Upside)
$22.17 (0.85% Upside)
Blogger Sentiment
Neutral
AMPH Sentiment 75%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 174.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $401.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 16.0%
Last 30 Days ▲ 16.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.92%
12-Months-Change
Fundamentals
Return on Equity
10.11%
Trailing 12-Months
Asset Growth
7.95%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
AMPH Company Deck
AMPH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mix of positive operational execution and material near-term challenges. Key positives include 5% revenue growth to $183.9M, gross margin expansion to 51%, successful new product launches (ipratropium bromide and other recent launches), strong BAQSIMI prescription growth (up ~17%) and a contract-year BAQSIMI milestone triggering a $100M payment in Q3. The company generated meaningful operating cash flow (~$51.3M) and repurchased ~$45M of stock, and advanced its development pipeline toward potential 2027 commercialization of the insulin aspart biosimilar and early-stage proprietary programs. On the negative side, the IMS FDA warning letter and related remediation will add $2–3M per quarter in expenses and could slow IMS sales and batch releases; glucagon sales declined sharply (-42% YoY) and several operating expense categories rose substantially (SG&A and G&A +30%). Management still maintained full-year sales guidance and emphasized diversification and U.S. manufacturing investments. Balancing the operational progress, financial improvements, and the notable regulatory and cost headwinds, the overall tone is cautiously constructive.View all AMPH earnings summariesAMPH Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$22.17
▲(0.85% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Viatris
―
Pacira Pharmaceuticals
―
Teva
―
ANI Pharmaceuticals
―
Amneal Pharmaceuticals
―
Ownership Overview
28.19% Insiders
21.72% Mutual Funds
0.25% Other Institutional Investors
23.41% Public Companies and
Individual Investors










